Skip to main content

Table 1 Baseline† clinical characteristics for all randomized women. Data are mean (SD) unless otherwise indicated

From: Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial

 

Duloxetine

Placebo

Randomized N‡

60

61

Age, years

56.31 (± 11.00)

52.59 (± 10.25)

BMI, kg/m2

24.98 (± 2.96)

24.89 (± 3.13)

IEF/week (SD) [range]

15.38 (± 9.11) [5.50–47.44]

15.23 (± 8.74) [7.00–56.58]

Mean time between voids§

179.36 (± 38.81)

193.32 (± 38.00)

I-QOL score

61.88 (± 19.84)

61.21 (± 22.71)

Previous continence surgery

3

5

  1. †Baseline is the last visit score on or prior to randomization.
  2. ‡Every randomized subject did not provide information for each variable; percentages are calculated using the number of responding women as the denominator.
  3. §P = 0.048.
  4. Abbreviations: BMI = body mass index; PFMT = pelvic floor muscle training; IEF = incontinence episode frequency; I-QOL = Incontinence Quality of Life questionnaire.